Frontlight ResearchEarly access
Lung cancer trials in Mexico
34 of 40 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Guadalajara, Mexico City, Monterrey, Oaxaca City
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 2/3Taking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Chihuahua City, Guadalajara, Mexico City, Monterrey, Oaxaca City, Puebla City, Querétaro, Tijuana, Zapopan
- Age
- 18 years and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - Phase 3Taking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- México, Mexico City, Monterrey, Oaxaca City, Querétaro
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 3Taking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Guadalajara, Mexico City, Puebla City, Veracruz de Ignacio de LA Llave
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - Phase 2/3Not yet taking people in MexicoStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Chihuahua City, Mexico City, Oaxaca City
- Age
- 18 years and over
- People
- 661 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080 - Phase 3Taking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Benito Juárez, Chihuahua City, Guadalajara, Mexico City, Monterrey, Oaxaca City, Puebla City
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - Phase 2Active, not recruitingStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Where
- Mexico City, Monterrey, Oaxaca City
- Age
- 18 years and over
- People
- 430 worldwide
- Run by
- Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00 - Phase 3Taking peopleA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Where
- Chihuahua City, Guadalajara, Monterrey, Oaxaca City
- Age
- 18 years and over
- People
- 780 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00 - Phase 3Active, not recruitingA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Where
- Guadalajara, Puebla City
- Age
- 18 years and over
- People
- 530 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00 - Phase 3Taking peopleA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- Where
- Guadajalara, Mexico City, San Pedro Garza García
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07099898 - Phase 3Not yet taking people in MexicoDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- Guadalajara, Jalisco, México, Mexico City, Monterrey, Nuevo León, Toluca
- Age
- 18 years and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00 - Phase 3Taking peopleA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Where
- Guadalajara, México, Querétaro, San Luis Potosí City
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Guadalajara, Mexico City
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06793215 - Phase 3Taking peopleA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Where
- Guadalajara, Mexico City, Oaxaca City, Puebla City
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00 - Phase 3Not yet taking people in MexicoA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Monterrey, Puebla City, Querétaro, Saltillo, Tijuana, Zapopan
- Age
- 18 years and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00 - Phase 3Taking peopleA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- Guadalajara, Juriquilla, León, Mexico City, Monterrey, Oaxaca City, Puebla City, San Pedro Garza García, Veracruz
- Age
- 18 years and over
- People
- 1,264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00 - Phase 3Not yet taking people in MexicoA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Mexico City, Monterrey, Naucalpan, Puebla City, San Pedro Garza García
- Age
- 18 years and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00 - Phase 3Taking peopleSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Where
- Guadalajara, Mexico City, Monterrey, Oaxaca City, Puebla City, San Luis Potosí City
- Age
- 18 years and over
- People
- 614 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00 - Phase 3Taking peopleBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Jalisco, México, Mexico City, Monterrey
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00 - Phase 2/3Taking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Guadalajara, Mexico City, Monterrey
- Age
- 18 years and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - Phase 3Taking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Guadalajara, Morelia, Oaxaca City
- Age
- 18 years and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - Phase 3Taking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Guadalajara, Mexico City, Monterrey, Pachuca, Puebla City, Saltillo, Veracruz
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - Phase 3Taking peopleStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Where
- Mexico City
- Age
- 18 years and over
- People
- 686 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00 - Phase 3Not yet taking people in MexicoA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Guadalajara, Mexico City, Monterrey, Oaxaca City, Puebla City, Querétaro, Zapopan
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - Phase 3Not yet taking people in MexicoA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- León, Mexico City, Mirador
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00